OncoCyte Corp Contracts & Agreements
104 Contracts & Agreements
- Business Finance (40 contracts)
- Business Operations (6)
- Human Resources (25)
- Intellectual Property (4)
- Mergers & Acquisitions (4)
- Real Estate (6)
- Uncategorized (19)
- Memorandum of Understanding, dated November 8, 2024, between the Company and Bio-Rad Laboratories, Inc (Filed With SEC on November 12, 2024)
- Amended and Restated 2018 Equity Incentive Plan (Filed With SEC on October 15, 2024)
- Securities Purchase Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto (Filed With SEC on October 3, 2024)
- Registration Rights Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto (Filed With SEC on October 3, 2024)
- Sales Agreement, dated August 9, 2024, by and between the Oncocyte Corporation and Needham & Company, LLC (Filed With SEC on August 9, 2024)
- Employment Agreement, dated May 20, 2024, by and between Oncocyte Corporation and Ekkehard Schtz (Filed With SEC on August 8, 2024)
- Employment Agreement, dated June 17, 2024, by and between Oncocyte Corporation and Andrea James (Filed With SEC on August 8, 2024)
- Collaboration Agreement, dated April 5, 2024, between the Company and Bio-Rad Laboratories, Inc (Filed With SEC on May 15, 2024)
- Description of Securities (Filed With SEC on April 16, 2024)
- Lease Agreement for Suite 103, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC (Filed With SEC on April 16, 2024)
- Lease Agreement for Suite 410, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC (Filed With SEC on April 16, 2024)
- Lease Agreement for Suite 510, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC (Filed With SEC on April 16, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on April 12, 2024)
- Securities Purchase Agreement, dated April 11, 2024, by and among the Company and the investors signatory thereto (Filed With SEC on April 12, 2024)
- Registration Rights Agreement, dated April 11, 2024, by and among the Company and the investors signatory thereto (Filed With SEC on April 12, 2024)
- Sublease Agreement, dated August 8, 2023, by and between Oncocyte Corporation and Induce Biologics USA, Inc (Filed With SEC on November 9, 2023)
- Amendment to Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated July 13, 2023 (Filed With SEC on July 14, 2023)
- Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated June 6, 2023 (Filed With SEC on June 9, 2023)
- Description of Securities (Filed With SEC on April 12, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on April 6, 2023)
- Second Amendment to Stock Purchase Agreement, dated February 16, 2023, by and among Dragon Scientific, LLC, Oncocyte Corporation and Razor Genomics Inc (Filed With SEC on February 23, 2023)
- Amendment No. 1 to Amended and Restated Agreement and Plan of Merger dated February 8, 2023, by and between Oncocyte Corporation and David MacKenzie, solely in his capacity as... (Filed With SEC on February 13, 2023)
- Termination Agreement, dated February 7, 2023, by and between Oncocyte Corporation and Life Technologies Corporation (Filed With SEC on February 13, 2023)
- First Amendment to Stock Purchase Agreement, dated December 15, 2022, by and among Dragon Scientific, LLC, Oncocyte Corporation and Razor Genomics Inc (Filed With SEC on February 3, 2023)
- Stock Purchase Agreement, dated December 15, 2022, by and among Dragon Scientific, LLC, Oncocyte Corporation and Razor Genomics Inc (Filed With SEC on December 21, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Gisela Paulsen, dated December 16, 2022 (Filed With SEC on December 21, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Douglas Ross, dated December 16, 2022 (Filed With SEC on December 21, 2022)
- Consulting Agreement, by and between the Company and Douglas Ross, dated as of December 16, 2022 (Filed With SEC on December 21, 2022)
- Separation Agreement and General Release of All Claims, by and between the Company and Ronald Andrews, dated December 1, 2022 (Filed With SEC on December 5, 2022)
- Consulting Agreement, by and between the Company and Ronald Andrews, dated as of December 1, 2022 (Filed With SEC on December 5, 2022)
- Employment Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)
- Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (Filed With SEC on December 5, 2022)
- Underwriting Agreement, dated April 13, 2022, between Oncocyte Corporation and BTIG, LLC, as representative of the underwriters named therein (Filed With SEC on April 19, 2022)
- Form of Warrant (Filed With SEC on April 19, 2022)
- Form of Securities Purchase Agreement, among us and certain investors, dated April 13, 2022 (Filed With SEC on April 13, 2022)
- Description of Securities (Filed With SEC on March 11, 2022)
- Collaboration Agreement, dated January 13, 2022, by and between Oncocyte Corporation and Life Technologies Corporation (Filed With SEC on March 11, 2022)
- Addendum No. 2 to Exclusive Sublicense Agreement in the PRC Territory, dated December 5, 2021, by and among Razor Genomics, Inc., Oncocyte Corporation, Encore Clinical, Inc., and... (Filed With SEC on December 8, 2021)
- Change in Control and Executive Severance Plan Agreement, dated October 4 2021, between Oncocyte Corporation and Gisela Paulsen (Filed With SEC on October 7, 2021)
- Amendment of 2018 Equity Incentive Plan (Filed With SEC on June 28, 2021)
- At-The-Market Sales Agreement, dated June 11, 2021, between OncoCyte Corporation and BTIG, LLC (Filed With SEC on June 14, 2021)
- Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021, by and among OncoCyte Corporation, CNI Monitor Sub,... (Filed With SEC on April 19, 2021)
- Description of Securities (Filed With SEC on March 19, 2021)
- Amended and Restated Exclusive License Agreement, effective February 15, 2018, between Razor Genomics, Inc. and the licensor named therein (Filed With SEC on March 19, 2021)
- Purchase Agreement, dated February 4, 2021, between OncoCyte Corporation and Piper Sandler & Co., as representative of the underwriters named therein (Filed With SEC on February 5, 2021)
- Agreement and Plan of Merger, dated as of February 2, 2021, among Oncocyte Corporation, CNI Monitor Sub, Inc., Chronix Biomedical, Inc., the Shareholders who became a Party to the... (Filed With SEC on February 3, 2021)
- Subscription Agreements, dated January 20, 2021, between OncoCyte Corporation and the investors named therein (Filed With SEC on January 21, 2021)
- Exclusive Sublicense Agreement in the PRC Territory (Filed With SEC on December 16, 2020)
- Reduction in Salary Agreement between OncoCyte Corporation and Albert Parker (Filed With SEC on September 28, 2020)
- Reduction in Salary Agreement between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on September 28, 2020)
- Reduction in Salary Agreement between OncoCyte Corporation and Tony Kalajian (Filed With SEC on September 28, 2020)
- Employment Agreement, dated March 23, 2020, between OncoCyte Corporation and Douglas Ross (Filed With SEC on July 29, 2020)
- Loan Deferral Agreement, dated April 2, 2020, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on May 12, 2020)
- Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Ronald Andrews (Filed With SEC on May 12, 2020)
- Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Mitchell Levine (Filed With SEC on May 12, 2020)
- Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on May 12, 2020)
- U.S. Small Business Administration Paycheck Protection Program Note (Filed With SEC on April 29, 2020)
- Form of Subscription Agreements, dated April 24, 2020, between OncoCyte Corporation and the investors named therein (Filed With SEC on April 28, 2020)
- Description of Securities (Filed With SEC on March 26, 2020)
- Employment Agreement, dated May 22, 2019, between OncoCyte Corporation and Padma Sundar (Filed With SEC on March 26, 2020)
- Lease Agreement, dated November 10, 2011, between Insight Genetics, Inc. and MPC Holdings, LLC, as renewed by notice dated January 3, 2019 (Filed With SEC on March 26, 2020)
- Oncocyte Corporation Change in Control and Severance Plan (Filed With SEC on March 26, 2020)
- Form of Change in Control and Severance Agreement (Filed With SEC on March 26, 2020)
- Equity Distribution Agreement, dated March 20, 2020 (Filed With SEC on March 20, 2020)
- Agreement and Plan of Merger, dated as of January 10, 2020, among Oncocyte Corporation, Cancer DX Sub, Inc., Insight Genetics, Inc., the Shareholders who became a Party to the... (Filed With SEC on February 5, 2020)
- Subscription Agreement, dated January 2, 2020, between Oncocyte Corporation and the investors named therein (Filed With SEC on January 6, 2020)
- Office Lease Agreement, dated December 23, 2019, between OncoCyte Corporation and Cushing Ventures, LLC (Filed With SEC on December 27, 2019)
- Form of Subscription Agreement between OncoCyte Corporation and the investors party thereto (Filed With SEC on November 14, 2019)
- First Amendment to Loan and Security Agreement, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on October 21, 2019)
- Warrant to Purchase Common Stock, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on October 21, 2019)
- Warrant to Purchase Shares of Common Stock, dated August 1, 2019 (Filed With SEC on August 14, 2019)
- Transition Agreement, dated July 1, 2019, between OncoCyte Corporation and William Annett (Filed With SEC on July 8, 2019)
- Employment Agreement, dated June 4, 2019, between OncoCyte Corporation and Ronald Andrews (Filed With SEC on June 6, 2019)
- Separation Agreement, dated January 22, 2019, between OncoCyte Corporation and Kristine Mechem (Filed With SEC on April 1, 2019)
- Purchase Agreement between OncoCyte Corporation and Piper Jaffray & Co. dated February 8, 2019 (Filed With SEC on February 12, 2019)
- Employment Agreement, dated August 6, 2018, between OncoCyte Corporation and Albert P. Parker (Filed With SEC on November 13, 2018)
- Form of Warrant (Filed With SEC on August 1, 2018)
- Form of Securities Purchase Agreement, dated July 26, 2018, by and among OncoCyte Corporation and the investors signatory thereto (Filed With SEC on August 1, 2018)
- Engagement Agreement, dated July 26, 2018, by and between OncoCyte Corporation and Chardan Capital Markets, LLC (Filed With SEC on August 1, 2018)
- Employment Agreement, dated November 15, 2017, between OncoCyte Corporation and Mitchell Levine (Filed With SEC on April 2, 2018)
- Employment Agreement, dated August 31, 2017, between OncoCyte Corporation and Michael Vicari (Filed With SEC on April 2, 2018)
- Form of Securities Purchase Agreement (Filed With SEC on March 29, 2018)
- WARRANT (Filed With SEC on July 26, 2017)
- WARRANT (Filed With SEC on July 26, 2017)
- WARRANT (Filed With SEC on July 26, 2017)
- WARRANT (Filed With SEC on July 26, 2017)
- WARRANTEXERCISE AGREEMENT (Filed With SEC on July 26, 2017)
- WARRANTEXERCISE AGREEMENT (Filed With SEC on July 26, 2017)
- WARRANTEXERCISE AGREEMENT (Filed With SEC on July 26, 2017)
- Employment Termination and Release Agreement, dated February 27, 2017, between OncoCyte Corporation and Karen Chapman (Filed With SEC on April 28, 2017)
- Form of 2017 Warrant, Exercise Price $3.25 (Filed With SEC on February 27, 2017)
- Form of 2017 Warrant, Exercise Price $5.50 (Filed With SEC on February 27, 2017)
- Silicon Valley Bank Warrant (Filed With SEC on February 27, 2017)
- Employment Agreement, dated November 1, 2016, between OncoCyte Corporation and Lyndal Hesterberg (Filed With SEC on February 27, 2017)
- Loan and Security Agreement, dated February 21, 2017, between OncoCyte Corporation and Silicon Valley Bank (Filed With SEC on February 27, 2017)
- Form of New Warrant (Filed With SEC on February 24, 2017)
- Form of Warrant Exercise Agreement (Filed With SEC on February 24, 2017)
- Alternate form of Warrant Exercise Agreement (Filed With SEC on February 24, 2017)
- Form of Warrants (Filed With SEC on August 29, 2016)
- Form of Securities Purchase Agreement (Filed With SEC on August 29, 2016)
- Alternate form of Securities Purchase Agreement (Filed With SEC on August 29, 2016)
- Second Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Filed With SEC on August 11, 2016)
- License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a... (Filed With SEC on March 30, 2016)
- First Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Filed With SEC on March 30, 2016)
